Skandinaviska Enskilda Banken AB publ Buys 116,758 Shares of DaVita Inc. (NYSE:DVA)

Skandinaviska Enskilda Banken AB publ increased its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 256.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 162,233 shares of the company's stock after purchasing an additional 116,758 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.20% of DaVita worth $24,301,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. SBI Securities Co. Ltd. bought a new stake in shares of DaVita during the fourth quarter worth approximately $41,000. Quarry LP bought a new stake in shares of DaVita during the third quarter worth approximately $60,000. Venturi Wealth Management LLC boosted its holdings in shares of DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after acquiring an additional 152 shares during the period. Versant Capital Management Inc boosted its holdings in shares of DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $68,000 after acquiring an additional 169 shares during the period. Finally, Blue Trust Inc. boosted its holdings in shares of DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after acquiring an additional 131 shares during the period. Institutional investors own 90.12% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on DVA shares. Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Cowen reiterated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $166.33.

Remove Ads

DaVita Price Performance

DVA traded up $0.03 during trading on Tuesday, hitting $149.27. 673,871 shares of the stock traded hands, compared to its average volume of 780,848. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60. The company has a market cap of $11.94 billion, a price-to-earnings ratio of 13.90, a PEG ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The business has a 50 day moving average price of $158.87 and a 200 day moving average price of $157.62.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.